Atracurium is a new non-depolarising neuromuscular blocking agent, metabolized through Hofmann elimination. A case is presented in which a 45-year-old patient with severe liver disease showed a decreased response to atracurium. The possible causes of resistance to atracurium are discussed. We conclude that atracurium may be used in patients with severe hepatic disease. © 1985 Canadian Anesthesiologists.
CITATION STYLE
Gyasi, H. K., & Naguib, M. (1985). Atracurium and severe hepatic disease: a case report. Canadian Anaesthetists’ Society Journal, 32(2), 161–164. https://doi.org/10.1007/BF03010043
Mendeley helps you to discover research relevant for your work.